Despite advances in systemic and biologic therapy, topical agents remain the primary treatment for most patients with plaque psoriasis. Dr. Bhutani-Jacques reviews the steroidal and non-steroidal armamentarium and the risks associated with prolonged corticosteroid use.
A 48-year-old man with chronic plaque psoriasis develops new intertriginous involvement unresponsive to prior topical regimens. Dr. Bhutani-Jacques outlines how lesion location and treatment history inform selection of a non-steroidal topical agent.
In this segment, Dr. Tina Bhutani-Jacques discusses the clinical rationale for transitioning patients with plaque psoriasis to newer nonsteroidal topical therapies when previous treatments have provided inadequate efficacy or tolerability.
In this episode, Dr. Tina Bhutani-Jacques presents the second case, featuring a 45-year-old woman with plaque psoriasis affecting both the scalp and body.
In this segment, Dr. Tina Bhutani-Jacques expands on the rationale for selecting roflumilast 0.3% foam for a patient with plaque psoriasis affecting both the scalp and body.
In the third case, Dr. Tina Bhutani-Jacques introduces a 34-year-old man with longstanding plaque psoriasis involving approximately 2% body surface area who remains frustrated by recurrent flares and visible plaques despite previous treatment with topical corticosteroids.
In the discussion, Dr. Tina Bhutani-Jacques reviews the management of a 34-year-old man with localized plaque psoriasis who is seeking effective long-term disease control while avoiding topical corticosteroids.
In the concluding segment, Dr. Tina Bhutani-Jacques discusses the rationale for initiating tapinarof 1% cream in a patient with localized plaque psoriasis who is unwilling to use topical corticosteroids because of concerns about long-term adverse effects.
